Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

This was a single center, single arm, phase II study. Patients with previously untreated follicular lymphoma were enrolled from the department of lymphoma, Tianjin Medical University Cancer Institute and Hospital. The bulky disease was received radiation (dose:18~24Gy) before RCHOP. Patients began chemoimmunotherapy 1~2 weeks later than radiation. Treatment included Tiselizumab (200 mg iv d1) plus R-CHOP (rituximab 375 mg/m2 intravenous \[IV\] day 2, cyclophosphamide 750 mg/m2 IV day 3, doxorubicin 50 mg/m2 IV day 3, vincristine 1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3, and prednisone 100 m

Trial Details

NCT ID
NCT06704555
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Follicular Lymphoma Lymphoma
Interventions
  • radiation therapy
  • Tiselizumab
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Histologically confirmed CD20 positive (+) follicular lymphoma, grade 1, 2, or 3a,bulky disease (Mass diameter ≥ 7 cm)
  • Have had no prior systemic treatment for lymphoma
  • Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment
  • Age 18-75 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Follicular Lymphoma Lymphoma Trials on Trialify →